Monte Rosa Therapeutics, Inc. GLUE Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- Monte Rosa Therapeutics, Inc. (GLUE) reported free cash flow of -$39.24M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s free cash flow changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s free cash flow increased by 16.7% year-over-year, from -$47.08M to -$39.24M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s free cash flow?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s free cash flow has grown at a -26.4% compound annual growth rate (CAGR), from -$69.1M to -$27.5M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.